Edition:
United Kingdom

Pharmaceuticals

Page 1

Jiang Zhong Pharmaceutical's Prelim 2017 Net Profit Up 10 Percent Y/Y

7:41am GMT

Jan 19 (Reuters) - Jiang Zhong Pharmaceutical Co Ltd <600750.SS>::SAYS PRELIM 2017 NET PROFIT UP 10 PERCENT Y/Y AT 418.0 MILLION YUAN ($65.38 million).

Roche Unit Chugai Says Gets Japanese Approval Of Tecentriq For Treatment Of Unresectable, Advanced Or Recurrent Non-Small Cell Lung Cancer

6:22am GMT

Roche Holding Ag ::ROCHE UNIT CHUGAI SAYS GETS JAPANESE APPROVAL OF TECENTRIQ FOR TREATMENT OF UNRESECTABLE, ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER.

European Commission Approves Amgen, Allergan's Mvasi

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Amgen Inc ::EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER.AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI.

European Commission Approves Amgen, Allergan's Mvasi

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Amgen Inc ::EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER.AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI.

Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

Thursday, 18 Jan 2018

Jan 18 (Reuters) - PHARMA MAR SA ::CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT.

Kite Announces Clinical Collaboration With Pfizer

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Gilead Sciences Inc ::KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA.GILEAD SCIENCES INC - KITE ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH PFIZER, INC.GILEAD SCIENCES INC - MULTI-CENTER PHASE 1/2 STUDY SPONSORED BY KITE IS EXPECTED TO BEGIN IN 2018.GILEAD SCIENCES INC - RESULTS OF STUDY WILL BE USED TO EVALUATE OPTIONS FOR FURTHER DEVELOPMENT OF THE COMBINATION, OR SIMILAR COMBINATIONS.

Torrent Pharmaceuticals Buys Bio-Pharm Inc

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Torrent Pharmaceuticals Ltd ::SAYS TORRENT PHARMA ACQUIRES BIO-PHARM INC.PLANS FURTHER INVESTMENTS TO EXPAND BIO-PHARM FACILITIES; WILL INCREASE NUMBER OF PRODUCT FILINGS FROM BIO-PHARM.

AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Azurrx Biopharma Inc ::AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - IN PARTNERSHIP WITH MAYOLY SPINDLER, RECEIVED REQUIRED APPROVALS TO ADD A FRENCH SITE TO PHASE IIA STUDY OF MS1819-SD.

Nuuvera Acquires License To Import Medical Cannabis To Italy

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Nuuvera Inc ::NUUVERA ACQUIRES ONE OF SEVEN ITALIAN CANNABIS LICENSES.NUUVERA INC - ‍LICENSE WAS ACQUIRED THROUGH PURCHASE OF 100 PERCENT OF ISSUED AND OUTSTANDING SHARES IN GENOA BASED FL-GROUP​.NUUVERA - ‍WITH PARTNERSHIP WITH FL-GROUP SECURED, CO INTENDS TO IMPORT CANNABIS FLOWER, AND INTRODUCE ITS BRANDED CANNABIS OIL TO ITALIAN MARKET​.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary